News | April 25, 2013

Medical Therapy Versus Angioplasty in Treating Stable Coronary Artery Disease

Population Health Management Medical Therapy Angioplasty Coronary Artery Disease

April 25, 2013 — The decision to perform an invasive procedure to open clogged arteries in the heart instead of first trying medication and lifestyle changes may not reduce a patient's risk of death or of a major cardiac event. Unnecessary procedures to treat chronic, stable heart disease contribute to rising healthcare costs. A targeted approach to avoiding this kind of overutilization by instead relying on evidence-based decision-making is presented in the peer-review journal Population Health Management. The article is available free on the Population Health Management website.

Lisa Behnke, M.D., MHA, BSN and coauthors from OptumHealth Care Solutions (Fort Myers, Fla., and Golden Valley, Minn.) and Jefferson School of Population Health (Philadelphia, Pa.) emphasize that whereas percutaneous coronary intervention (PCI) may be a lifesaving procedure for patients with an acute coronary event, it may not be more beneficial in stable coronary artery disease than more conservative treatment approaches, yet it has become increasingly common over the past 30 years.

In the article "A Targeted Approach to Reducing Overutilization: Use of Percutaneous Coronary Intervention in Stable Coronary Artery Disease," the authors present a model for shared decision-making in which physicians and patients together consider the various treatment options, what each involves, their risks and a comparison of the outcomes associated with each according to the latest evidence published in the medical literature.

"This study is a prime example of how comparative effectiveness research offers the promise of improved quality and safety, as well as lower cost," says Editor-in-Chief David B. Nash, M.D., MBA, dean and Dr. Raymond C. and Doris N. Grandon professor, Jefferson School of Population Health, Philadelphia, Pa. "Better informed decisions means the right treatments will be given to the right patients. This means fewer complications and shorter hospitalizations."

For more information: www.liebertpub.com/bari 

Related Content

DISRUPT BTK Study Shows Positive Results With Lithoplasty in Calcified Lesions Below the Knee
News | Peripheral Artery Disease (PAD)| September 20, 2017
Shockwave Medical reported positive results from the DISRUPT BTK Study, which were presented at the annual...
Heart Failure Market to Surpass $16 Billion by 2026
News | Heart Failure| September 19, 2017
The heart failure space across the seven key markets of the U.S., France, Germany, Italy, Spain, the U.K. and Japan is...
Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Fysicon Receives FDA Approval for QMAPP Hemodynamic Monitoring System
Technology | Hemodynamic Monitoring Systems| September 18, 2017
Fysicon announced that it has been granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its...
Marijuana Associated With Three-Fold Risk of Death From Hypertension
News | Hypertension| September 14, 2017
Marijuana use is associated with a three-fold risk of death from hypertension, according to research published recently...
Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Feature | Cath Lab| September 14, 2017
September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials
Mississippi Surgical and Vascular Center Uses Toshiba Ultimax-i FPD to Save Patients' Limbs
News | Angiography| September 14, 2017
The southern U.S. sees some of the highest numbers of chronic medical conditions, such as peripheral artery disease...
Sponsored Content | Videos | Structural Heart Occluders| September 13, 2017
Ziyad Hijazi, M.D., MPH, MSCAI, FACC, director of the cardiac program and chair of the Department of Pediatrics at Si
Overlay Init